MA34387B1 - Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté - Google Patents
Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydratéInfo
- Publication number
- MA34387B1 MA34387B1 MA35575A MA35575A MA34387B1 MA 34387 B1 MA34387 B1 MA 34387B1 MA 35575 A MA35575 A MA 35575A MA 35575 A MA35575 A MA 35575A MA 34387 B1 MA34387 B1 MA 34387B1
- Authority
- MA
- Morocco
- Prior art keywords
- benzimidazol
- fluoro
- amino
- methylpiperrazin
- quinolin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- BSYNFGPFPYSTTM-UHFFFAOYSA-N 2-hydroxypropanoic acid;hydrate Chemical compound O.CC(O)C(O)=O BSYNFGPFPYSTTM-UHFFFAOYSA-N 0.000 title 1
- -1 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinoline monolactate Chemical compound 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur une composition pharmaceutique pour administration orale comprenant du monolactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinoline-2-one monohydraté, une charge à hauteur de 15 à 70 % en poids, un délitant à hauteur de moins de 15 % en poids, un glissant et/ou un lubrifiant à hauteur de 0,1 à 10 % en poids, les quantités en poids étant basées sur le poids total de la composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10168028 | 2010-06-30 | ||
| PCT/EP2011/060949 WO2012001074A2 (fr) | 2010-06-30 | 2011-06-29 | Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34387B1 true MA34387B1 (fr) | 2013-07-03 |
Family
ID=42751565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35575A MA34387B1 (fr) | 2010-06-30 | 2011-06-29 | Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US9545402B2 (fr) |
| EP (2) | EP3446686A1 (fr) |
| JP (1) | JP6043281B2 (fr) |
| KR (2) | KR101840182B1 (fr) |
| CN (2) | CN106943355B (fr) |
| AR (1) | AR081776A1 (fr) |
| AU (1) | AU2011273519B2 (fr) |
| BR (1) | BR112012033479A8 (fr) |
| CA (1) | CA2801826C (fr) |
| CL (1) | CL2012003729A1 (fr) |
| CO (1) | CO6650354A2 (fr) |
| CR (1) | CR20120623A (fr) |
| CU (1) | CU20120177A7 (fr) |
| DK (1) | DK2588086T3 (fr) |
| DO (1) | DOP2012000324A (fr) |
| EA (1) | EA026244B1 (fr) |
| EC (1) | ECSP13012411A (fr) |
| ES (1) | ES2701161T3 (fr) |
| GE (1) | GEP20146049B (fr) |
| GT (1) | GT201200348A (fr) |
| HU (1) | HUE042355T2 (fr) |
| IL (1) | IL223799A (fr) |
| MA (1) | MA34387B1 (fr) |
| MX (1) | MX345404B (fr) |
| MY (2) | MY163369A (fr) |
| NI (1) | NI201200189A (fr) |
| NZ (1) | NZ604055A (fr) |
| PE (1) | PE20130481A1 (fr) |
| PH (1) | PH12012502519A1 (fr) |
| PL (1) | PL2588086T3 (fr) |
| PT (1) | PT2588086T (fr) |
| SG (1) | SG186182A1 (fr) |
| TN (1) | TN2012000574A1 (fr) |
| TR (1) | TR201818761T4 (fr) |
| TW (1) | TWI583384B (fr) |
| UA (1) | UA109659C2 (fr) |
| UY (1) | UY33472A (fr) |
| WO (1) | WO2012001074A2 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013063003A1 (fr) | 2011-10-28 | 2013-05-02 | Novartis Ag | Méthode de traitement des tumeurs stromales gastro-intestinales |
| KR20140117457A (ko) | 2012-01-31 | 2014-10-07 | 노파르티스 아게 | Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도 |
| RU2015104537A (ru) | 2012-07-11 | 2016-08-27 | Новартис Аг | Способы лечения стромальных опухолей желудочно-кишечного тракта |
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| WO2014058785A1 (fr) | 2012-10-10 | 2014-04-17 | Novartis Ag | Polythérapie |
| DK2968529T3 (da) * | 2013-03-14 | 2020-10-12 | Aimmune Therapeutics Inc | Fremstilling af jordnøddeformuleringer til oral desensibilisering |
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| AU2014348502B2 (en) | 2013-11-15 | 2019-08-15 | Tangible Science, Inc. | Contact lens with a hydrophilic layer |
| WO2015187736A1 (fr) * | 2014-06-02 | 2015-12-10 | Allergen Research Corporation | Formulations placebo et utilisations de celles-ci |
| EP3229851A4 (fr) | 2014-12-09 | 2018-08-01 | Tangible Science LLC | Revêtement de dispositif médical avec une couche biocompatible |
| TWI829098B (zh) | 2015-01-02 | 2024-01-11 | 美商梅拉洛伊卡公司 | 細菌組成物 |
| KR20180008511A (ko) * | 2015-05-22 | 2018-01-24 | 노파르티스 아게 | 제약 조성물 |
| KR102753602B1 (ko) | 2017-11-02 | 2025-01-10 | 에이뮨 테라퓨틱스, 인코퍼레이티드 | 경구 면역요법 방법 |
| EP3836801A4 (fr) | 2018-08-16 | 2022-05-18 | Société des Produits Nestlé S.A. | Immunothérapie orale de désensibilisation à l'arachide avec dose d'entretien |
| JP2022514645A (ja) | 2018-12-20 | 2022-02-14 | アイミューン セラピューティクス，インコーポレイテッド | ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール |
| CN113966229A (zh) | 2019-05-10 | 2022-01-21 | 爱沐疗法公司 | 用于改善花生过敏患者的生活质量的方法 |
| US10835531B1 (en) | 2019-06-18 | 2020-11-17 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| MX2022007945A (es) * | 2019-12-24 | 2022-10-03 | Hanmi Pharm Ind Co Ltd | Formulacion compleja que comprende sitagliptina y dapagliflozina, y metodo de preparacion de la misma. |
| WO2022026851A1 (fr) * | 2020-07-31 | 2022-02-03 | The Scripps Research Institute | Dégradation d'arn ciblée permettant une redéfinition de précision de médicaments à petites molécules à ciblage protéique pour l'arn |
| CN119745892A (zh) * | 2023-09-27 | 2025-04-04 | 南京迈诺威医药科技有限公司 | 含有别孕烷醇酮衍生物的药物组合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5009897A (en) * | 1988-06-24 | 1991-04-23 | Abbott Laboratories | Pharmaceutical granules and tablets made therefrom |
| JP4361727B2 (ja) | 2000-09-11 | 2009-11-11 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | チロシンキナーゼインヒビターとしてのキノリノン誘導体 |
| CA2496164C (fr) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Quinolinones de benzimidazole et leurs utilisations |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| GB0504203D0 (en) * | 2005-03-01 | 2005-04-06 | Novartis Ag | Organic compounds |
| EP2270000B1 (fr) * | 2005-05-23 | 2015-07-29 | Novartis AG | Formes cristallines et autres de sels d'acide lactique 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one |
| KR20080039876A (ko) * | 2005-07-22 | 2008-05-07 | 미리어드 제네틱스, 인크. | 높은 약물 충진 제형 및 투여형 |
| BRPI0619370A2 (pt) | 2005-11-29 | 2011-09-27 | Novartis Ag | formulações de quinolinonas |
| CN101316593B (zh) * | 2005-11-29 | 2012-05-02 | 诺瓦提斯公司 | 喹啉酮类的制剂 |
| RU2009136669A (ru) | 2007-03-09 | 2011-04-20 | Новартис АГ (CH) | Лечение меланомы |
| EP2205244B1 (fr) | 2007-11-08 | 2013-08-21 | Ambit Biosciences Corporation | Procédés d'administration de n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-éthoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]phényl}urée pour traiter une maladie proliférative |
| PE20091628A1 (es) | 2008-03-19 | 2009-11-19 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona |
| EP2108365A1 (fr) * | 2008-04-09 | 2009-10-14 | LEK Pharmaceuticals d.d. | Formule pharmaceutique à dosage simple comportant du mesylate d'eprosartan |
| JP2013525292A (ja) | 2010-04-16 | 2013-06-20 | ノバルティス アーゲー | 有機化合物の組合せ |
-
2011
- 2011-06-28 UY UY0001033472A patent/UY33472A/es not_active Application Discontinuation
- 2011-06-28 AR ARP110102271A patent/AR081776A1/es unknown
- 2011-06-29 PE PE2012002517A patent/PE20130481A1/es not_active Application Discontinuation
- 2011-06-29 PT PT11734043T patent/PT2588086T/pt unknown
- 2011-06-29 KR KR1020177035178A patent/KR101840182B1/ko not_active Expired - Fee Related
- 2011-06-29 CN CN201710208616.1A patent/CN106943355B/zh active Active
- 2011-06-29 JP JP2013517282A patent/JP6043281B2/ja active Active
- 2011-06-29 AU AU2011273519A patent/AU2011273519B2/en active Active
- 2011-06-29 CN CN2011800320095A patent/CN103068373A/zh active Pending
- 2011-06-29 HU HUE11734043A patent/HUE042355T2/hu unknown
- 2011-06-29 EP EP18193864.8A patent/EP3446686A1/fr active Pending
- 2011-06-29 NZ NZ604055A patent/NZ604055A/en not_active IP Right Cessation
- 2011-06-29 MA MA35575A patent/MA34387B1/fr unknown
- 2011-06-29 PH PH1/2012/502519A patent/PH12012502519A1/en unknown
- 2011-06-29 GE GEAP201112986A patent/GEP20146049B/en unknown
- 2011-06-29 CA CA2801826A patent/CA2801826C/fr active Active
- 2011-06-29 US US13/703,120 patent/US9545402B2/en active Active
- 2011-06-29 MY MYPI2012005339A patent/MY163369A/en unknown
- 2011-06-29 EA EA201291410A patent/EA026244B1/ru not_active IP Right Cessation
- 2011-06-29 PL PL11734043T patent/PL2588086T3/pl unknown
- 2011-06-29 MX MX2012015091A patent/MX345404B/es active IP Right Grant
- 2011-06-29 SG SG2012089413A patent/SG186182A1/en unknown
- 2011-06-29 BR BR112012033479A patent/BR112012033479A8/pt not_active Application Discontinuation
- 2011-06-29 KR KR1020137002390A patent/KR20130091319A/ko not_active Ceased
- 2011-06-29 DK DK11734043.0T patent/DK2588086T3/en active
- 2011-06-29 TW TW100122927A patent/TWI583384B/zh not_active IP Right Cessation
- 2011-06-29 ES ES11734043T patent/ES2701161T3/es active Active
- 2011-06-29 WO PCT/EP2011/060949 patent/WO2012001074A2/fr not_active Ceased
- 2011-06-29 UA UAA201213966A patent/UA109659C2/uk unknown
- 2011-06-29 EP EP11734043.0A patent/EP2588086B1/fr active Active
- 2011-06-29 TR TR2018/18761T patent/TR201818761T4/tr unknown
- 2011-11-29 MY MYPI2016002052A patent/MY177741A/en unknown
-
2012
- 2012-12-05 TN TNP2012000574A patent/TN2012000574A1/en unknown
- 2012-12-11 CR CR20120623A patent/CR20120623A/es unknown
- 2012-12-20 IL IL223799A patent/IL223799A/en active IP Right Grant
- 2012-12-20 NI NI201200189A patent/NI201200189A/es unknown
- 2012-12-21 GT GT201200348A patent/GT201200348A/es unknown
- 2012-12-21 DO DO2012000324A patent/DOP2012000324A/es unknown
- 2012-12-24 CU CU2012000177A patent/CU20120177A7/es unknown
- 2012-12-27 CO CO12234898A patent/CO6650354A2/es not_active Application Discontinuation
- 2012-12-28 CL CL2012003729A patent/CL2012003729A1/es unknown
-
2013
- 2013-01-30 EC ECSP13012411 patent/ECSP13012411A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012001074A3 (fr) | Compositions pharmaceutiques comprenant du lactate de 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoline-2-one monohydraté | |
| MA38576B2 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
| FR2944448B1 (fr) | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| EP2717914A4 (fr) | Formulation à libération prolongée pour administration de protéines à l' il, et leurs procédés de préparation | |
| EP3356522A4 (fr) | Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants | |
| EP3866767A4 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| MA34727B1 (fr) | Imidazolylimidazoles condensés utilisés comme composés antiviraux | |
| EP3661968A4 (fr) | Plateforme de nanoparticules pour administration d'anticorps et de vaccin | |
| EP2889032A4 (fr) | Composition pour la prévention ou le traitement d'une maladie rénale comprenant un dérivé de pyrazole | |
| EP2906243A4 (fr) | Compositions et procédés pour l'administration prolongée d'agents thérapeutiques tels que des agonistes du récepteur glp-1 | |
| MA34067B1 (fr) | Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer | |
| EP2679242A4 (fr) | Adjuvant pour l'administration transdermique ou transmuqueuse et préparation pharmaceutique le contenant | |
| EP3908251A4 (fr) | Compositions d'administration de produits pharmaceutiques et utilisations correspondantes | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| EP3773900A4 (fr) | Analogues d'hinokitiol, procédés de préparation et compositions pharmaceutiques de ceux-ci | |
| MA34806B1 (fr) | Compositions pharmaceutiques | |
| MA32602B1 (fr) | Utilisation de dronedarone pour la preparation d'un medicament pour la prevention d'un accident vasculaire cerebral ou un accident ischemique transitoire | |
| MA34952B1 (fr) | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme | |
| MA34106B1 (fr) | Combinaison de composés organiques | |
| EP2433987A4 (fr) | Composition destinée à la préparation de formulations d'émulsion ou de microémulsion | |
| EP3843785A4 (fr) | Compositions comprenant des stimulants de la perméation pour l'administration de médicaments | |
| EP2672985A4 (fr) | Compositions pharmaceutiques à base d'anakinra, exemptes de citrates | |
| EP3326628A4 (fr) | Composition pharmaceutique pour l'administration par voie orale comprenant un taxane à haute concentration | |
| MA34977B1 (fr) | Composés à base de complexes de FE(III) pour le traitement et la prévention de carences en fer et d'anémies dues à une carence en fer. |